Operational Costs Compared: SG&A Analysis of CRISPR Therapeutics AG and Ligand Pharmaceuticals Incorporated

A Comparative Analysis of SG&A Expenses: CRISPR Therapeutics AG vs. Ligand Pharmaceuticals

In the ever-evolving biotech industry, operational efficiency is key to sustaining growth and innovation. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent players: CRISPR Therapeutics AG and Ligand Pharmaceuticals Incorporated, from 2014 to 2023.

CRISPR Therapeutics AG has seen a remarkable increase in SG&A expenses, peaking in 2021 with a 1,900% rise from 2014. This surge reflects their aggressive expansion and investment in cutting-edge gene-editing technologies. In contrast, Ligand Pharmaceuticals exhibited a steadier growth, with a 210% increase over the same period, indicating a more conservative approach to operational spending.

By 2023, CRISPR's expenses slightly declined, suggesting a strategic shift towards optimizing costs. Meanwhile, Ligand's expenses remained stable, underscoring their consistent operational strategy. This comparison highlights the diverse strategies within the biotech sector, offering insights into how companies balance innovation with financial prudence.